VCARE PHARMATECH

Jiangsu Vcare PharmaTech Co., Ltd.(Jiangsu Vcare), established in 2010, is a high-tech biopharmaceutical company dedicated to addressing unmet clinical needs through differentiated innovation in drug and advanced therapy development. Since our inception, we’ve experienced rapid growth and evolved into a group-style enterprise with a strong foundation in two core business segments: innovative drug R&D and comprehensive pharmaceutical industry chain services. With 15 years of experience and a forward-looking mindset, Jiangsu Vcare continues to shape the future of biopharma through technology, quality, and purpose-driven innovation.

Learn More →

INNOVATIVE DRUGS

Jiangsu Vcare's proprietary innovative drug R&D business adheres to a differentiated strategy addressing unmet clinical needs. Based on innovative approaches including "overcoming therapeutic resistance", "resolving drug resistance", and "enhancing target selectivity", the company has established a tiered pipeline architecture centered on Vicagrel. Currently, it possesses five Class I innovative drugs in clinical development: VC004 capsules (oral anti-tumor targeted therapy); Vicagrel capsules (oral anti-thrombotic agent); VC005 tablets (oral immunomodulatory and anti-inflammatory agent); VC005 gel (topical immunomodulatory and anti-inflammatory formulation). Additionally, multiple preclinical projects are progressing through the pipeline, with therapeutic focuses spanning cardiovascular/cerebrovascular diseases, oncology, and autoimmune/inflammatory disorders. This strategic portfolio positions the company for comprehensive coverage of global pharmaceutical markets in the future.

INNOVATION PLATFORM

Innovative Drugs - Medicine - Pharmacy - Chemistry; Covering The Entire Life Cycle Of New Drug Research And Development

Learn More →

NEWS

VC005 Topical Gel is to Launch Phase III Trials! Jiangsu Vcare’s Fourth Independently Developed Innovative Drug will enter the Confirmatory Clinical Stage

2026-03-13

Recently, VC005 Topical Gel, a second-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), has received ethical approval for its Phase III clinical trial. The Phase III study for the treatment of mild-to-moderate atopic dermatitis (AD) will soon be initiated, marking a pivotal milestone as this differentiated innovative topical drug advances into the confirmatory clinical stage.

Efficient Progress! Jiangsu Vcare Completed Patient Enrollment in Phase II Clinical Trial of VC005 Tablets, a Second-Generation Highly Selective JAK1 Inhibitor for Vitiligo

2026-03-13

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has successfully completed patient enrollment in a Phase II clinical trial of VC005 Tablets, an independently developed second-generation highly selective JAK1 inhibitor, for the oral administration of non-segmental vitiligo (NSV).

Crack the Challenge of Alopecia！Jiangsu Vcare Secures IND Approval in China for VC005 Tablets, a Next-Generation Selective JAK1 Inhibitor, in Alopecia Areata

2026-02-02

Recently, a major R&D milestone has been achieved for VC005 Tablets, a second-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare). The project has officially obtained IND approval from the CDE of the NMPA of China, which is intended for the oral treatment of alopecia areata, bringing a brand-new therapeutic hope to patients suffering from hair loss.

Company Address:

No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China

Subsidiary NJVcare Website：

en.njvcare.com

Scan to see

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

SEO

Powerby：www.300.cn nanjing.300.cn